Adar1 Capital Management, Llc Purchases 6,400 Shares of NextCure (NASDAQ:NXTC) Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 6,400 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The shares were purchased at an average cost of $4.95 per share, for a total transaction of $31,680.00. Following the purchase, the insider owned 389,856 shares in the company, valued at $1,929,787.20. This represents a 1.67% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Wednesday, July 29th, Adar1 Capital Management, Llc bought 3,410 shares of NextCure stock. The shares were purchased at an average price of $5.00 per share, with a total value of $17,050.00.
• On Monday, July 27th, Adar1 Capital Management, Llc bought 7,798 shares of NextCure stock. The stock was purchased at an average cost of $5.00 per share, with a total value of $38,990.00.

NextCure Price Performance

NASDAQ NXTC opened at $5.03 on Friday. The company has a market cap of $18.17 million, a P/E ratio of -0.29 and a beta of 1.42. The stock has a 50-day moving average of $3.56 and a two-hundred day moving average of $8.72. NextCure, Inc. has a 1-year low of $1.55 and a 1-year high of $15.74.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.10) by $0.23. On average, analysts anticipate that NextCure, Inc. will post -7.89 EPS for the current fiscal year.

Hedge Funds Weigh In On NextCure

Large investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new stake in NextCure in the fourth quarter valued at $160,000. Millennium Management LLC acquired a new position in shares of NextCure during the 4th quarter worth about $185,000. Geode Capital Management LLC boosted its position in shares of NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after acquiring an additional 3,636 shares in the last quarter. Cable Car Capital LP increased its holdings in shares of NextCure by 13.1% in the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of NextCure by 18.7% in the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after acquiring an additional 5,300 shares during the last quarter. Hedge funds and other institutional investors own 42.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on NXTC shares. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of NextCure in a report on Wednesday, July 15th. Wall Street Zen downgraded shares of NextCure from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings lowered NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. Finally, Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $19.00.

NextCure Company Profile

NextCure, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large?scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.